Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 30:17:1541-1549.
doi: 10.2147/PPA.S350760. eCollection 2023.

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

Gemma Camiña-Conforto  1 , Laura Mateu-Arrom  1 , Anna López-Ferrer  1 , Lluís Puig  1
Affiliations
Review

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

Gemma Camiña-Conforto et al. Patient Prefer Adherence. .

Abstract

Psoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be unsatisfactory or lost with time, leading to discontinuation of treatment. Bimekizumab is a humanized monoclonal antibody that specifically inhibits both interleukin (IL)-17A and IL-17F. The efficacy and safety of bimekizumab in moderate-to-severe plaque psoriasis has been demonstrated in Phase 2 and Phase 3 clinical trials. Bimekizumab may offer some advantages over other biological treatments, making it especially indicated for certain patients. This narrative review aims to summarize the latest published evidence on the use of bimekizumab for the treatment of moderate-severe plaque psoriasis, focusing on patient selection and therapeutic perspectives. Bimekizumab has been shown to be more efficacious than adalimumab, secukinumab and ustekinumab in clinical trials, with high estimated probabilities of achieving complete (approximately 60%) or almost complete clearance (approximately 85%) of psoriasis at weeks 10-16, and a good safety profile. Response to bimekizumab is usually fast and maintained in the long term for both biologic-naive patients and those resistant to previous biologic treatments. The usual maintenance dose of 320 mg every 8 weeks makes bimekizumab especially convenient for non-compliant patients. Moreover, the efficacy and safety of bimekizumab have also been demonstrated in psoriasis affecting challenging-to-treat areas, psoriatic arthritis and hidradenitis suppurativa. In conclusion, dual inhibition of IL-17A and IL-17F with bimekizumab is a good therapeutic option for moderate-to-severe psoriasis.

Keywords: bimekizumab; biological therapy; interleukin-17; patient compliance; patient selection; psoriasis.

PubMed Disclaimer

Conflict of interest statement

G. Camiña-Conforto has received honoraria as a speaker for Sun Pharma and UCB. L. Mateu-Arrom does not have any potential conflicts of interest involving the work under consideration for publication. A. López-Ferrer has received honoraria as a speaker, in consultancies and in participation as an investigator in clinical trials for AbbVie, Almirall, Amgen, Janssen, Novartis, Eli Lilly, Leo Pharma and UCB. L. Puig has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Biogen, BIOCAD, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Samsung-Bioepis, Sandoz, Sanofi, and UCB.

Figures

Figure 1
Figure 1
PRISMA diagram of the systematic review process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48(6):732–740. doi:10.1111/1346-8138.15840 - DOI - PMC - PubMed
    1. Ruggiero A, Potestio L, Camela Snr E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. - PMC - PubMed
    1. Vidal S, Puig L, Carrascosa-Carrillo JM, González-Cantero Á, Ruiz-Carrascosa JC, Velasco-Pastor AM. From Messengers to Receptors in Psoriasis: the Role of IL-17RA in Disease and Treatment. Int J Mol Sci. 2021;22(13):6740. - PMC - PubMed
    1. Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777–1792. - PMC - PubMed
    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. - PubMed